Industry Sessions

2 May 2021

2 May 2021, 17:00 – 18:30

Merz Therapeutics
Expert Perspectives: A First-Line Treatment for Chronic Sialorrhea and Why Immunogenicity Matters with Botulinum Toxin

  • Welcome and introduction (Ernest Britton)
  • First and Only Botulinum Toxin Type A for Adults with Chronic Sialorrhea (Stuart Isaacson)
  • Why Immunogenicity Matters with Botulinum Toxin (Warner Carr)

2 May 2021, 17:00 – 18:30

Sunovion
Navigating the Treatment Options for “OFF” Episodes in Parkinson’s Disease: The Role of On-Demand Treatments

  • Welcome & Introductions, & Rules of the Debate (Stuart Isaacson)
  • On-Demand Treatments Should Be Utilized as Rescue Therapies After Other Adjunctive Therapies (Rajesh Pahwa)
  • On-Demand Treatments Should be Utilized Early Following the Onset of “OFF” Episodes (Fernando L. Pagan)
  • Live Panel Discussion/Q&A

3 May 2021

3 May 2021, 16:45 – 18:15

Sunovion
KYNMOBI® (apomorhpine HCL) Sublingual Film: Deep Dive into Clinical Data

  • KYNMOBI® (apomorhpine HCL) Sublingual Film: Deep Dive into Clinical Data (Diego Torres)
  • Q&A Discussion

3 May 2021, 16:45 – 18:15 

Britannia Pharmaceuticals LTD
Lifting the burden of advanced Parkinson’s – progress in device-aided therapies

  • Welcome & introductions; Treating advanced Parkinson’s disease (PD) – a multifaceted challenge (Teus van Laar)
  • The hidden burden of Parkinson’s disease progression – minimising the impact on patients and their care network (Maja Trost)
  • Optimising quality of life in advanced PD – the importance of timely identification and referral (Tove Henriksen)
  • Developing effective CDS strategies – advances in device-aided therapies (Jost Wolfgang)
  • Live Q&A with faculty

Status: 09.04.2021. Program subject to change.